---
title: "Theriva Biologics doses first patient in VIRAGE2 Phase 2a trial of VCN-01 for metastatic pancreatic cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295106175.md"
description: "Theriva Biologics has initiated dosing for the first patient in its VIRAGE2 Phase 2a trial. This study evaluates more frequent repeat dosing of VCN-01 combined with standard chemotherapy for first-line metastatic pancreatic cancer. The trial aims to refine dosing regimens for a potential future Phase 3 program, building on prior Phase 2b results. Initial safety and tolerability data are expected in Q3 2027, with enrollment completion targeted for H2 2026."
datetime: "2026-08-06T12:13:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295106175.md)
  - [en](https://longbridge.com/en/news/295106175.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295106175.md)
generator: "portal-rs"
---

# Theriva Biologics doses first patient in VIRAGE2 Phase 2a trial of VCN-01 for metastatic pancreatic cancer

-   Theriva Biologics began dosing in VIRAGE2, a Phase 2a trial testing more frequent repeat dosing of VCN-01 with standard chemotherapy in first-line metastatic pancreatic cancer. \* The study aims to refine the dosing regimen for a potential future pivotal Phase 3 program, following earlier Phase 2b VIRAGE results already reported. \* VIRAGE2 will not present efficacy results now; initial safety, tolerability, and pharmacodynamic readouts are expected in Q3 2027. \* The program builds on prior data suggesting repeat dosing could improve outcomes versus chemotherapy alone, without detailing performance metrics. \* Enrollment is expected to finish in H2 2026, setting a key timing marker for the company’s pancreatic cancer strategy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-091674), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TOVX.US](https://longbridge.com/en/quote/TOVX.US.md)

## Related News & Research

- [HC Wainwright Starts Theriva (TOVX) at Buy on Undervalued Oncolytic Virus Platform and Advancing VCN-01 Pancreatic Cancer Program](https://longbridge.com/en/news/295697080.md)
- [Theriva Biologics wins Spanish regulator clearance for VIRAGE2 VCN-01 pancreatic cancer trial](https://longbridge.com/en/news/291928699.md)
- [Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer](https://longbridge.com/en/news/296095129.md)
- [RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers](https://longbridge.com/en/news/296039942.md)
- [Dogwood Therapeutics to host virtual KOL event on Halneuron for chemotherapy-induced neuropathic pain](https://longbridge.com/en/news/296106790.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**